Achillion Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ACHN)

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) released its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.00. View Achillion Pharmaceuticals' Earnings History.

Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Achillion Pharmaceuticals.

4 brokerages have issued twelve-month target prices for Achillion Pharmaceuticals' stock. Their forecasts range from $2.50 to $6.30. On average, they anticipate Achillion Pharmaceuticals' stock price to reach $5.03 in the next year. This suggests that the stock has a possible downside of 18.3%. View Analyst Price Targets for Achillion Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achillion Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Achillion Pharmaceuticals.

Headlines about ACHN stock have been trending somewhat negative recently, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Achillion Pharmaceuticals earned a news sentiment score of -1.7 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Achillion Pharmaceuticals.

Achillion Pharmaceuticals saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 8,030,000 shares, a drop of 6.6% from the August 30th total of 8,600,000 shares. Based on an average daily volume of 1,780,000 shares, the short-interest ratio is currently 4.5 days. Currently, 5.9% of the company's stock are sold short. View Achillion Pharmaceuticals' Current Options Chain.

Some companies that are related to Achillion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHK), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NE), Gilead Sciences (GILD), Eiger Biopharmaceuticals (EIGR), Iconix Brand Group (ICON), ACADIA Pharmaceuticals (ACAD), Edap Tms (EDAP) and Celldex Therapeutics (CLDX).

Achillion Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Meeder Asset Management Inc. (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Achillion Pharmaceuticals stock include & Johnson Johnson and Joseph Truitt. View Institutional Ownership Trends for Achillion Pharmaceuticals.

ACHN stock was acquired by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc. and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Achillion Pharmaceuticals.

Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACHN stock can currently be purchased for approximately $6.16.

Achillion Pharmaceuticals has a market capitalization of $860.51 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-70,270,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Achillion Pharmaceuticals employs 56 workers across the globe.View Additional Information About Achillion Pharmaceuticals.

The official website for Achillion Pharmaceuticals is http://www.achillion.com/.

Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.